Bridgeway Capital Management’s Editas Medicine EDIT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$318K Sell
123,882
-2,118
-2% -$6.21K 0.01% 905
2026
Q2
$408K Hold
126,000
– – 0.01% 898
2026
Q1
$311K Buy
126,000
+50,000
+66% +$106K 0.01% 921
2025
Q4
$156K Hold
76,000
– – ﹤0.01% 1058
2025
Q3
$264K Sell
76,000
-44,000
-37% -$123K 0.01% 958
2025
Q2
$264K Buy
120,000
+100,000
+500% +$164K 0.01% 899
2025
Q1
$23.2K Sell
20,000
-130,000
-87% -$191K ﹤0.01% 1150
2024
Q4
$190K Buy
+150,000
New +$382K ﹤0.01% 1021

Other funds holding EDIT

Bridgeway Capital Management's EDIT Position: Q3 2026 in Review

Bridgeway Capital Management reduced its Editas Medicine (EDIT) stake by 1.7% in Q3 2026, selling an estimated $6.21K and leaving 123,882 shares worth $318K. The position accounts for 0.01% of the portfolio, ranked #905.

Bridgeway Capital Management first reported a position in EDIT in Q4 2024 and has held it in 8 quarters since. The position peaked at $408K in Q2 2026. 221 funds tracked by Wall St. Rank hold EDIT as of Q3 2026.

  • Bridgeway Capital Management held 123,882 shares of Editas Medicine worth $318K as of Q3 2026.
  • Bridgeway Capital Management sold 2,118 Editas Medicine shares in Q3 2026, an estimated $6.21K.
  • Editas Medicine made up 0.01% of Bridgeway Capital Management's portfolio in Q3 2026, its #905 holding.
  • Bridgeway Capital Management first reported a position in Editas Medicine in Q4 2024 and has held it in 8 quarters since.
  • Bridgeway Capital Management's Editas Medicine position peaked at $408K in Q2 2026.
  • 221 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2026.

Based on Bridgeway Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.